Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

SpeeDx receives FDA clearance for Mycoplasma genitalium product

SpeeDx Pty Ltd
Posted on: 19 Apr 18

SYDNEY, Australia, April 19, 2018 (GLOBE NEWSWIRE) -- SpeeDx's  Resistance Plus ®  MG Positive Control kit has now been listed with the US Food and Drug Administration (FDA) for sale in the United States through the company's recently incorporated US entity, SpeeDx Inc. The announcement coincides with the FDA registration of the Australian parent company - SpeeDx Pty Ltd - as a Medical Device Manufacturing Establishment, and clinical trials remain on-track for the  Resistance Plus  MG assay. *

The  Resistance Plus  MG Positive Control kit contains synthetic DNA to simulate  Mycoplasma genitalium , as well as five mutations known to confer resistance to macrolide antibiotics. Macrolide-resistant  M. genitalium  is a challenging sexually transmitted infection (STI), and global management guidelines are currently being adapted to deal with the rise in resistance. "This is an important product in our portfolio," said Elisa Mokany, Chief Technology Officer for SpeeDx. " M. genitalium  is very difficult to culture, and positive material for quality control can be hard to come by."  

SpeeDx's  Resistance Plus  MG assay is the first commercially available diagnostic test that simultaneously detects  M. genitalium  and genetic markers for antimicrobial resistance, and has been widely adopted across Europe, Australia and New Zealand since gaining CE marking in 2016. "We have a strong focus on tackling the global antimicrobial resistance problem," said Colin Denver, CEO of SpeeDx. "STIs are set to become the first incurable bacterial infections, and our  Resistance Plus  line of diagnostic tests empowers clinicians to make informed treatment decisions."

About  Mycoplasma genitalium

M. genitalium  can cause symptoms such as urethritis, cervicitis, endometritis and pelvic inflammatory disease. In recent studies, it has been found to have a higher prevalence than gonorrhoea. Like gonorrhoea,  M. genitalium  is evolving into a so-called STI superbug that is becoming resistant to many antibiotic treatments, leading to exceedingly difficult-to-treat infections and threatening global public health.

Macrolide antibiotics, specifically azithromycin, are the first-line treatments for the rapidly growing problem of  M. genitalium  STIs, but resistance to these antibiotics has increased by up to 60 percent in several countries. This development led guidelines on  M. genitalium  infections in Europe and Australia recommending the molecular detection of  M. genitalium  be complemented with an assay capable of detecting macrolide resistance-associated mutations.

About SpeeDx

Founded in 2009, SpeeDx is an Australian-based private company with offices in London and the US, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease. Currently, SpeeDx markets the only CE-marked and TGA approved commercial molecular test for the STI  M. genitalium (ResistancePlus ®  MG * ) that combines detection of the disease with detection of markers for antibiotic resistance. 
For more information about SpeeDx please see:  http://plexpcr.com

*   Not available in the US

Contacts for SpeeDx:
Madeline O'Donoghue
madelineo@speedx.com.au
+61 2 8212 8512 (ext 008)



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: SpeeDx Pty Ltd via GlobeNewswire
HUG#2185372
GlobeNewswire
globenewswire.com

Last updated on: 20/04/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.